2026.4.24
A Growth Model Built in the Infectious Disease FieldーShionogi & Co.'s Strategic Transformation and Value Creation
This month, we will dive into Shionogi & Co., Ltd. (4507), focusing on its corporate profile and Cadira's engagement activities.
Company History
Shionogi & Co. is a research-driven pharmaceutical company with over 140 years of history, founded in 1878 in Doshomachi, Osaka. The founder, Gisaburo Shionogi, was born in 1854 as the son of a wholesale drug merchant, and established "Shionogi Gisaburo Shoten" at the age of 24. The company was renamed Shionogi Shoten in 1919 and Shionogi & Co. in 1943, the name it carries today.
From the late 1950s, Shionogi established a strong position in antibacterial and antibiotic drugs, carving out a distinctive niche with infectious diseases at the core of its business. Performance deteriorated in the 1990s amid declining demand for antibiotics, but the company re-accelerated its path to growth in the 2000s and 2010s by partnering with overseas companies to bring a cholesterol treatment (2003) and an HIV therapy (2013) to global markets. In the fiscal year ended March 2025, royalty income from overseas sales — primarily HIV-related — accounted for more than half of total revenues, at ¥244.7 billion out of ¥438.3 billion. This highly efficient business model has produced an operating profit margin of 36%.
CEO Isao Teshirogi’s Track Record
For most of the period from its founding through 2008, Shionogi was led by members of the founding Shionogi family. In 2008, however, Isao Teshirogi — the current president and the first non-family leader — assumed the role. Having worked in R&D and overseas postings before serving as head of corporate planning under his predecessor Motomichi Shionogi, Teshirogi contributed to the structural reforms that established the company's current focus on small-molecule drugs and infectious diseases. His capabilities were recognized, and he was appointed president at the unusually young age of 48 for a major Japanese corporation.
With the U.S. patent on its flagship cholesterol drug Crestor (rosuvastatin) set to expire in 2016, Teshirogi negotiated with AstraZeneca — which handled overseas sales — to renegotiate the contract in 2014: accepting a lower royalty rate in exchange for an extended payment period. This smoothed the revenue decline from the patent cliff, while a parallel strategy of growing new drugs filled the gap. The HIV drug Tivicay (dolutegravir), approved in the United States in 2013, was the key product that gained growth momentum during this period. Developed in collaboration with GlaxoSmithKline (GSK) and commercialized by GSK's subsidiary ViiV Healthcare, Shionogi receives royalties from ViiV for its global reach. Teshirogi's ability to navigate patent cliffs adroitly through partnerships with AstraZeneca and GSK while sustaining a growth trajectory is genuinely worthy of recognition.
Transition to an Active Investment Phase
Entering 2025, Shionogi has moved into an offensive strategic phase, deploying the cash accumulated through its HIV royalty model. In May 2025, the company acquired Japan Tobacco Inc.'s (JT, 2914) pharmaceutical business along with its subsidiary Torii Pharmaceutical (4551) in a single transaction, aimed at expanding its R&D workforce and strengthening its domestic earnings base. In December 2025, it acquired the ALS treatment edaravone business from Tanabe Pharma (formerly Mitsubishi Tanabe Pharma) — an acquisition intended not only to add a new drug but also to gain expertise in rare disease operations. Then in January 2026, the company announced an increase in its stake in ViiV Healthcare from approximately 10% to 21.7%. Combined, these three transactions amount to roughly ¥900 billion — a transformative commitment for a company that, as of the fiscal year ended March 2025, had total assets of ¥1.5 trillion and net cash of ¥620 billion.
In line with its stated strategy of making rare diseases the second pillar alongside its infectious disease franchise, the company reports having actively explored acquisitions for about three years before these deals converged in quick succession. Integration of the JT and Torii businesses appears to be proceeding smoothly, and the lessons learned are expected to inform the edaravone integration process, which begins in earnest from April onwards.
The Social Value Shionogi Creates
Shionogi is an unusual type of pharmaceutical company — one that has grown by focusing on small-molecule infectious disease drugs, a space that most global pharma majors have retreated from. Small-molecule drugs tend to command lower prices, and demand for infectious disease therapies fluctuates significantly with outbreak patterns, making it a particularly challenging area in which to sustain high, stable profitability. Yet given that pandemics and antimicrobial resistance have not been eliminated, there remains clear social significance in continuing to develop drugs in this space. Shionogi's portfolio — including the influenza treatment Xofluza (baloxavir), the COVID-19 treatment Xocova (ensitrelvir), and the novel antibiotic Fetroja (cefiderocol) — demonstrates a genuine contribution to societal stability through drugs that address high-priority infectious disease needs.
The company's global access strategy for its core HIV franchise also merits attention. In low-income countries with high HIV burdens — particularly across Africa — Shionogi supports patient access through flexible patent arrangements and supply at near-cost pricing, while generating the vast majority of revenues from advanced markets, primarily the United States. This structure, in which profits from high-income markets effectively subsidize access in lower-income regions, represents a compelling model for reconciling commercial sustainability with social purpose. While much of this work is operationally carried out by ViiV Healthcare as the commercialization partner, Shionogi deserves recognition for its meaningful role as the innovator underpinning those efforts.
Cadira’s Engagement
Cadira has been actively deepening its dialogue with Shionogi since last year. Investor meetings with pharmaceutical companies can easily gravitate toward pipeline discussions alone, but Cadira deliberately broadens the conversation to encompass corporate strategy and sustainability. In our most recent meeting, we highlighted how Shionogi has pivoted from a cash-rich balance sheet posture to a leveraged, large-scale investment stance — a shift we characterized as a clear and meaningful change of corporate phase. We also conveyed our strong resonance with the company's commitment to social purpose as expressed through its infectious disease focus and its pharmaceutical access initiatives.
In response, Shionogi shared that our engagement had prompted fresh reflection — offering an outside perspective on the validity of their growth strategy and the adequacy of their disclosure practices. We take this as an indication that our dialogue has served as a genuine catalyst for the company to reassess its approach to management and communication through an external lens.
We intend to continue this constructive engagement, with the aim of contributing to Shionogi's sustainable long-term value creation.
Learn More
2026/7/16
Turning Social Challenges into Growth — Optex Group's Competitiveness and Value Creation Through Engagement
We introduce Optex Group (6914), including a company overview and Cadira's ongoing engagement activi...
2026/6/23
Turning Environmental Value into Growth- Daiseki’s Circular Business Model and the Source of Its Competitive Advantage
We spotlight Daiseki Co., Ltd. — providing an overview of the company and an account of Cadira's eng...
2026/5/21
The Essence of Quality-Oriented Management – Insights into Long-Term Value from a Dialogue with Sysmex
This month, we spotlight Sysmex Corporation (6869) — providing an overview of the company and the on...
2026/5/14
Survey on Cybersecurity Governance Systems (2026Q1)
In recent years, the cybersecurity risks facing companies have entered a new phase. In April 2026, U...
2026/4/24
A Growth Model Built in the Infectious Disease FieldーShionogi & Co.'s Strategic Transformation and Value Creation
This month, we will dive into Shionogi & Co., Ltd. (4507), focusing on its corporate profile and...
2026/3/19
A Growth Model Born from Social Issues – Park24's Value Creation and Investment Perspective
This month, we will dive into Park24 Co., Ltd. (4666), focusing on its corporate profile and Cadira'...
2026/2/20
Deepening Sustainability Dialogue — Survey Findings Highlight Qualitative Shifts in IR
Survey OverviewCadira Capital Management conducts a sustainability-related survey following IR meeti...
2026/2/20
Diversity Driving Japan’s Vision as an Asset Management Nation — Cadira’s Role in Partnership with IMC
The Independent Managers Club (IMC) is a research and advocacy organization launched in October 2023...
2026/1/26
The Educational Foundation for Human Capital - A Dialogue Between Insource and Cadira
This month, we will dive into Insource Co., Ltd. (6200), focusing on its corporate profile and Cadir...
2025/12/12
Supporting Social Stability Through Technological Advancement — Our Dialogue with Macnica Holdings
This month, we introduce Macnica Holdings, Inc. (3132), covering its corporate profile and our engag...
2025/11/28
AI-Related Corporate Survey: Internal Training and Policy Status at 34 Listed Companies
At Cadira Capital Management, we conduct surveys after IR meetings with listed companies, focusing o...
2025/10/24
TDK’s Timeless Evolution: Corporate Culture and Value Creation Revealed Through Our Dialogue
(Center: CIO Yu Shimizu, at TDK Internal Event)For nearly 90 years since its founding, TDK has conti...
2025/9/26
Collaborative Dialogue Supporting Sustainability Strategy — The Case of Kokuyo
Cadira supports the sustainable, long-term growth of its portfolio companies through collaborative d...
2025/8/29
Evolving IR Practices in Japan: Insights from Cadira’s Q2 2025 Survey
At Cadira Capital Management, we conduct ongoing surveys with listed companies following our IR meet...
2025/8/22
Report on Our Annual Conference (July 3, 2025)
On July 3, 2025, Cadira Capital Management hosted its annual conference to reflect on activities dur...
2025/7/18
Mitigation and Adaptation in Action: Why Weathernews Inc. Stands Out
At Cadira Capital Management, we believe companies that integrate environmental impact with business...
2025/6/20
From Disclosure to Dialogue: What We Learned from Publishing Our Progress Report 2024
Since the publication of our inaugural Progress Report 2024 in March, we have held discussions ...
2025/5/22
Building on Three Pillars — How Sekisui House Integrates Innovation, Sustainability, and Global Expansion
At Cadira, we place importance not only on regular IR meetings but also on engaging directly with co...
2025/5/22
Aligning Incentives for Sustainable Growth — Results from Our Survey on Equity-Based Compensation
At Cadira Capital Management, our investment management team conducts post-IR meeting surveys with t...
2025/5/15
Engagement as a Catalyst for Corporate Renewal — Insights from KDDI
Cadira has maintained an ongoing dialogue with KDDI Corporation (hereinafter “KDDI”). Our CIO, Mr. S...
2025/4/25
Bridging the Gap in Sustainability Dialogue for Smaller Companies — The Case of Econavista
Cadira Capital Management engages in constructive and neutral dialogue on the identification of corp...
2025/4/23
EMP Roundtable: The Current Status and Potential of EMP in Cultivating the Next Generation of Asset Managers (Part 2)
Participants:Mr. Hiroyuki Nomura, Operating Officer, Senior General Manager, Investment Planning Dep...
2025/4/23
EMP Roundtable: The Current Status and Potential of EMP in Cultivating the Next Generation of Japanese Asset Managers (Part 1)
Participants:Mr. Hiroyuki Nomura, Operating Officer, Senior General Manager, Investment Planning Dep...
2025/4/11
Redefining Work: Timee’s Social Impact in Japan’s Labor Market
Cadira engages in deep dialogue with Timee, Inc. (hereinafter "Timee"), placing a strong emphasis on...
2025/3/14
Lecture on Impact Integration Methods in Listed Equity Investments
At Cadira Capital Management, we actively share our investment approach to foster greater impact ori...
2025/2/21
From Umami to Impact: How Ajinomoto Aligns Growth with Global Sustainability Goals
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2025/2/14
Strengthening Human Capital: Insights from Cadira’s Investor–Company Dialogue
Cadira’s investment team conducts post-meeting surveys following IR meetings.These surveys include q...
2025/1/23
Sysmex: Advancing Global Healthcare Through Innovation and Engagement
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/12/13
Leadership Renewal and the Path to Sustainable Value at Optex Group
Optex Group is a manufacturer of sensors for indoor and outdoor security, automatic doors, and indus...
2024/11/29
Connecting the Investment Chain: Market Dialogue with Marui Group and Katitas
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/10/25
IR Survey Results 2024Q3: Rising Wages and the Business Case for Social Impact
We conduct a survey for respondents following IR meetings. The survey covers impressions of the meet...
2024/10/25
Our Activities in September 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/9/24
Our Activities in August 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/8/23
Our Activities in July 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/7/26
IR Survey Results 2024Q2: SSBJ Sector Classifications and the Evolving Role of Sustainability in Corporate Strategy
We conduct a survey for respondents following IR meetings. The survey covers impressions of the meet...
2024/7/19
Our Activities in June 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/6/21
Our Activities in May 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/5/24
Our Activities in April 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/4/26
IR Survey Results 2024Q1: How Japanese Companies Are Measuring Their Impact
Cadira's investment management team conducts a survey of respondents following IR meetings. In addit...
2024/4/19
Our Activities in March 2024
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/3/29
Our Comments to the "Capital Markets Disclosure and Dialogue Guidance for Impact Companies
The Japan National Advisory Board of the Global Steering Group for Impact Investment (GSG-NAB Japan)...
2024/3/15
"Make Home the Happiest Place in the World" — Sekisui House’s Landmark Acquisition and Cadira’s Perspective
On January 18, Sekisui House announced the acquisition of M.D.C. Holdings ("MDC"), a leading U.S. ho...
2024/3/15
Engagement Supporting Brand Renewal and Business Transformation — The Case of Kanadevia (formally Hitachi Zosen)
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/2/23
Survey Result from Our Investor Relations Meetings (2023Q4)
At Cadira Capital Management, we ask our contacts to fill out a survey after each Investor Relations...
2024/2/16
From Revitalizing Vacant Homes to Creating Social Impact — Engagement with KATITAS
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2024/1/12
Our Activities in December 2023
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2023/12/15
Our Activities in November 2023
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2023/11/10
Our Activities in October 2023
At Cadira Capital Management, our mission is "Connecting the Investment Chain and Beyond". Collabora...
2023/10/27
Survey Result from Our Investor Relations Meetings (2023Q3)
At Cadira Capital Management, we ask our contacts to fill out a survey after each Investor Relations...
2023/10/23
Our Comments to the “Draft Basic Guidelines on Impact Investment” by the Financial Services Agency of Japan
On June 30, 2023, the Financial Services Agency of Japan released the "Draft Basic Guidelines on Imp...
Important Notice
The content of this website has been prepared by Cadira Capital Management Co., Ltd. (“CCM”) for informational purposes only to professional investors who are expected to make their own investment decisions without undue reliance on such content. The views and strategies described may not be suitable for all investors. Under no circumstances is it to be used or considered as legal or investment advice, a recommendation to buy, an offer to sell, or a solicitation of an offer to buy or sell securities and investors should be advised to consult their own stockbroker, accountant, solicitor, independent financial adviser, or other professional adviser for advice. We accept no liability whatsoever for any direct or consequential loss arising from any use of this content. The information is intended solely to report on investment strategies and opportunities identified by CCM. Opinions and estimates offered constitute our judgment and are subject to change without notice, as are statements of financial market trends, which are based on current market conditions. CCM and its affiliates do not warrant the accuracy or completeness of any of the information or data contained herein. References to specific securities and their issuers are for illustrative purpose only and are not intended to be, and should not be interpreted as investment advice or, a recommendation, offer or solicitation for the purpose or sale of any financial investment. This content does not constitute tax advice and as such investors should be advised to consult their own tax advisers regarding the tax consequences of their investment activities. Investment return and principal will fluctuate, so that a client's initial investment may increase or decrease. Investing in securities markets involve risks like those arising from stock and bond markets, currency exchanges rate and interest rate volatility. No part of this content may, without CCM prior written consent, be copied, reproduced, or published by any recipient for any purpose. Past performance is not indicative of future performance.
